Also trades as: 0K1R.L (LSE) · $vol 0M
VRDN Smart Money
Viridian Therapeutics, Inc.
1W: +12.2%
1M: +14.0%
3M: +19.6%
YTD: -23.9%
1Y: +5.8%
3Y: +98.5%
5Y: +40.4%
$24.09
+0.75 (+3.21%)
After Hours: $22.26 (-1.83, -7.60%)
Weekly Expected Move ±9.1%
$18
$20
$22
$24
$26
Credit Risk of going bust: higher than 62% of companies Debt: 8.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.32 (down 99%), Viridian Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242.9M against a stock market value of $2.64B.
Distance to default 4.10 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $121.8M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 0.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.32 (down 99%), Viridian Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242.9M against a stock market value of $2.64B.
Distance to default 4.10 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $121.8M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 0.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026271
Institutions Holding
+0 vs prior
91.1%
Ownership
+9.84%
50
New
95
Increased
104
Reduced
54
Closed
👔 Insider Trades
13 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Tousignant Jennifer | officer: chief legal officer | S-Sale | 4,212 | $24.50 | $103K | Filing |
| 2026-08-19 | Tousignant Jennifer | officer: chief legal officer | S-Sale | 10,000 | $24.50 | $245K | Filing |
| 2026-05-11 | Fairmount Funds Management LLC | director | P-Purchase | 1,176,470 | $17.00 | $20.0M | Filing |
| 2026-05-11 | Fairmount Healthcare Fund II GP LLC | director | P-Purchase | 1,176,470 | $17.00 | $20.0M | Filing |
| 2026-05-11 | Fairmount Healthcare Fund II L.P. | director | P-Purchase | 1,176,470 | $17.00 | $20.0M | Filing |
| 2026-03-03 | Beetham Thomas W. | officer: chief operating officer | F-Tax Withholding | 3,138 | $29.32 | $92K | Filing |
| 2026-03-03 | Harmon Seth | officer: chief financial officer | F-Tax Withholding | 2,091 | $29.32 | $61K | Filing |
| 2026-03-03 | Mahoney Stephen F. | officer: president and ceo | F-Tax Withholding | 7,627 | $29.32 | $224K | Filing |
| 2026-03-03 | Tousignant Jennifer | officer: chief legal officer | F-Tax Withholding | 1,724 | $29.32 | $51K | Filing |
| 2025-12-31 | Tousignant Jennifer | officer: chief legal officer | S-Sale | 2,272 | $31.16 | $71K | Filing |
| 2025-10-23 | Fairmount Funds Management LLC | director | P-Purchase | 454,545 | $22.00 | $10.0M | Filing |
| 2025-10-23 | Fairmount Healthcare Fund II GP LLC | director | P-Purchase | 454,545 | $22.00 | $10.0M | Filing |
| 2025-10-23 | Fairmount Healthcare Fund II L.P. | director | P-Purchase | 454,545 | $22.00 | $10.0M | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| FMR LLC | 16,604,740 | $305M | +1,225,363 | 2026-06-30 | Filing |
| BlackRock, Inc. | 8,551,488 | $157M | +720,013 | 2026-06-30 | Filing |
| Bellevue Group AG | 6,731,909 | $124M | +5,765 | 2026-06-30 | Filing |
| Paradigm Biocapital Advisors LP | 6,723,788 | $124M | +3,574,895 | 2026-06-30 | Filing |
| Kynam Capital Management, LP | 6,453,877 | $119M | +4,112,225 | 2026-06-30 | Filing |
| STATE STREET CORP | 6,124,976 | $113M | +1,452,091 | 2026-06-30 | Filing |
| Fairmount Funds Management LLC | 5,090,928 | $94M | +1,176,470 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,576,860 | $84M | +409,659 | 2026-06-30 | Filing |
| Deep Track Capital, LP | 3,592,740 | $66M | +2,198,796 | 2026-06-30 | Filing |
| Venrock Adviser, LLC | 3,257,917 | $60M | -624,792 | 2026-06-30 | Filing |
| WELLINGTON MANAGEMENT GROUP LLP | 3,128,362 | $57M | +49,808 | 2026-06-30 | Filing |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,752,827 | $51M | +1,111,350 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2,501,869 | $46M | +168,656 | 2026-06-30 | Filing |
| Avoro Capital Advisors LLC | 2,500,000 | $46M | +1,000,000 | 2026-06-30 | Filing |
| BAKER BROS. ADVISORS LP | 2,383,025 | $44M | +411,347 | 2026-06-30 | Filing |
| Point72 Asset Management, L.P. | 2,343,208 | $43M | +2,020,372 | 2026-06-30 | Filing |
| Caligan Partners LP | 2,193,981 | $40M | +2,193,981 | 2026-06-30 | Filing |
| NOVO HOLDINGS A/S | 2,135,000 | $39M | +135,000 | 2026-06-30 | Filing |
| TANG CAPITAL MANAGEMENT LLC | 1,792,626 | $33M | — | 2026-06-30 | Filing |
| Fisher Asset Management, LLC | 1,750,850 | $32M | -17,445 | 2026-06-30 | Filing |